Bright Minds Biosciences Inc.

CNSX:DRUG Stock Report

Market Cap: CA$296.6m

Bright Minds Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

CNSX:DRUG Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
02 Apr 25SellCA$120,960Jan PedersenIndividual2,400CA$50.40
28 Feb 25SellCA$261,185Nils BottlerIndividual5,000CA$52.24
06 Dec 24SellCA$1,411,795Jan PedersenIndividual25,000CA$56.47
12 Nov 24SellCA$911,145Nils BottlerIndividual16,000CA$56.95
08 Nov 24SellCA$400,010Ryan E. S. CheungIndividual5,000CA$80.18
05 Nov 24SellCA$732,150Alex VasilkevichIndividual10,000CA$73.21
05 Nov 24SellCA$376,117Nils BottlerIndividual5,400CA$77.93
04 Nov 24BuyCA$5,694,446Jeremy FryzukIndividual188,940CA$30.14
04 Nov 24BuyCA$5,555,536Cormorant Asset Management, LPCompany184,331CA$30.14
04 Nov 24BuyCA$138,910Jeremy FryzukIndividual4,609CA$30.14
30 Oct 24SellCA$231,911Nils BottlerIndividual3,600CA$67.86
16 Oct 24BuyCA$4,455,497Cormorant Asset Management, LPCompany422,591CA$34.74
16 Oct 24BuyCA$6,797,471Cormorant Asset Management, LPCompany875,000CA$32.30
16 Oct 24SellCA$12,087,914Ian McDonaldIndividual300,000CA$40.29
15 Oct 24SellCA$96,696Jeremy FryzukIndividual2,400CA$40.29

Insider Trading Volume

Insider Buying: DRUG insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of DRUG?
Owner TypeNumber of SharesOwnership Percentage
VC/PE Firms864,47812.1%
Individual Insiders1,588,35922.2%
Hedge Funds2,066,89328.9%
Institutions2,627,18436.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 57.8%.

Top Shareholders

Top 25 shareholders own 101.12% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.8%
Janus Henderson Group plc
1,111,368CA$46.8m118%0.01%
15%
Cormorant Asset Management, LP
1,059,331CA$44.6m0%2.28%
14.3%
Ian McDonald
1,004,900CA$42.3m3.08%no data
7.21%
Sio Capital Management, LLC
507,562CA$21.4m12.3%5.1%
7.1%
Commodore Capital LP
500,000CA$21.1m0%1.19%
6.82%
Alan Kozikowski
480,500CA$20.2m0%no data
6.54%
RA Capital Management, L.P.
460,829CA$19.4m0%0.2%
5.73%
Perceptive Advisors LLC
403,649CA$17.0m0%0.39%
3.57%
Vivo Capital, LLC
251,572CA$10.6m0%0.6%
3.48%
Logos Global Management, L.P.
245,000CA$10.3m0%1.02%
2.38%
Morgan Stanley, Investment Banking and Brokerage Investments
167,640CA$7.1m0%no data
2.16%
Ikarian Capital, LLC
152,211CA$6.4m0%1.6%
1.92%
Point72 Asset Management, L.P.
135,189CA$5.7m0%0.01%
1.88%
Adage Capital Management, L.P.
132,500CA$5.6m0%0.01%
1.46%
Walleye Capital LLC
103,192CA$4.3m0%0.02%
0.99%
Schonfeld Strategic Advisors LLC
69,812CA$2.9m0%0.01%
0.98%
Acuta Capital Partners, LLC
69,124CA$2.9m0%2.48%
0.86%
Springhill Fund Asset Management (HK) Company Limited
60,648CA$2.6m0%3.08%
0.82%
Jan Pedersen
57,600CA$2.4m64.6%no data
0.63%
Boothbay Fund Management, LLC
44,580CA$1.9m0%0.05%
0.57%
Millennium Management LLC
40,379CA$1.7m0%no data
0.29%
Jeremy Fryzuk
20,609CA$867.9k-89.4%no data
0.28%
Alex Vasilkevich
19,750CA$831.7k0%no data
0.21%
Atika Capital Management, LLC
15,000CA$631.7k0%0.06%
0.14%
UBS Asset Management AG
10,161CA$427.9k198%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/02 18:20
End of Day Share Price 2025/05/02 00:00
Earnings2024/12/31
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bright Minds Biosciences Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Charles DuncanCantor Fitzgerald & Co.
Sepehr ManochehryEight Capital